Facebook Twitter LinkedIn Google Plus RSS

Pharma company with site in Princeton is acquired

By ,

Gallus BioPharmaceuticals LLC, a St. Louis company with facilities in Princeton, was acquired by DPx Holdings B.V., the companies announced Thursday.

Gallus is a manufacturer of biologic drugs, while DPx is the parent of Patheon, a pharmaceutical services business. The two Gallus sites will become the first Patheon biologic drug substance sites in the U.S., according to a news release, complementing the DPx unit’s existing sites in the Netherlands and Australia.

"We are pleased to expand our biologics business with the acquisition of Gallus BioPharmaceuticals," Jim Mullen, CEO of DPx Holdings, said in the release. "This transaction is in line with our strategy. We can now further support the needs of our customers with biologics projects by providing flexibility, leading technology solutions, commercial operations and an expanded footprint with two U.S. sites."

The deal is expected to close in the fourth quarter. Terms were not disclosed.


Rutgers to debut $120,000, 30-second promo ad

Study: N.J. is top 10 for site selection websites

Rutgers survey finds recession took toll on Americans' spirit

More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy